CD8A and prostate cancer: By contrast, a Genetic Algorithm computational approach identified a subset of five flow cytometry features (CD8+CD45RA−CD27−CD28− (CD8+ Effector Memory cells); CD4+CD45RA−CD27−CD28− (CD4+ Terminally Differentiated Effector Memory Cells re-expressing CD45RA); CD3−CD19+ (B cells); CD3+CD56+CD8+CD4+ (NKT cells)) from a set of twenty features, which could potentially discriminate between benign disease and prostate cancer.